1 09, 2020 Marta Schirripa et al., KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population adlitterio663392024-04-10T14:40:15+02:00 Leggi di più
21 07, 2020 Umberto Malapelle et. al., Predictive molecular pathology in the time of coronavirus disease Diatech Pharmacogenetics2020-11-03T14:14:46+01:00 Leggi di più
29 06, 2020 Marco Mammana et. al., Outcome of patients with colorectal cancer undergoing lung metastases resection: a single-institution retrospective analysis Diatech Pharmacogenetics2020-11-03T14:34:16+01:00 Leggi di più
16 05, 2020 Alessandro Parisi et. al., Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study Diatech Pharmacogenetics2020-11-03T15:11:21+01:00 Leggi di più
7 05, 2020 Elisabetta Zulato et. al., Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer Diatech Pharmacogenetics2020-11-03T15:24:44+01:00 Leggi di più
31 07, 2019 Sergio Migliore et al., Large-scale PRNP genotyping of small ruminants using an automated high-throughput MALDI-TOF MS assay. Diatech Pharmacogenetics2020-01-22T12:17:44+01:00 Leggi di più
2 05, 2019 Paola Bordi et al., From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC Diatech Pharmacogenetics2020-01-22T12:42:02+01:00 Leggi di più
29 04, 2019 Michela Notarangelo et al., Ultrasensitive detection of cancer biomarkers by nickel-based isolation of polydisperse extracellular vesicles from blood Diatech Pharmacogenetics2020-01-22T12:22:34+01:00 Leggi di più
11 04, 2019 Enrico Mini et al., RNA sequencing reveals PNN and KCNQ1OT1as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy Diatech Pharmacogenetics2020-01-22T12:23:58+01:00 Leggi di più
14 02, 2019 Lorenza Rimassa et al., Phase 2 study of tivantinib and cetuximab in KRAS wild-type metastatic colorectal cancer patients with acquired resistance to EGFR inhibitors and emergence of MET overexpression: lesson learned for future trials with EGFR/MET dual inhibition Diatech Pharmacogenetics2020-01-22T12:34:31+01:00 Leggi di più
